ROQUEFORT THERAPEUTICS PLC

Board/Management Information • Jul 20, 2022

National Storage Mechanism | Additional information

RNS Number : 0445T

Roquefort Therapeutics PLC

20 July 2022

20 July 2022

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Appointment of Joint Broker

Roquefort Therapeutics (LSE:ROQ,OTCQB:ROQAF), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to announce the appointment of  Hybridan LLP ("Hybridan") as its Joint Broker with immediate effect.

Stephen West, Roquefort Therapeutics Executive Chairman, commented:

"We are delighted to be working with Hybridan going forward.  Hybridan has a deep understanding of the life sciences sector particularly within small caps, and their experience will be invaluable to Roquefort Therapeutics as we target further institutional investors and family offices."

-Ends-

Enquiries:

Roquefort Therapeutics plc
Stephen West (Chairman)	+44 (0)20 3290 9339
Hybridan LLP (Joint Broker) Claire Louise Noyce Optiva Securities Limited (Joint Broker)	+44 (0)203 764 2341
Christian Dennis Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale	+44 (0)20 3411 1881 +44 (0)20 7466 5000

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.

LEI: ‎254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma.  The Company is focused on developing first in class Midkine inhibiting drugs for the treatment of cancer. 

Through extensive research resulting in validation through publication in over 1,000 scientific publications, Roquefort Therapeutics has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of significant unmet needs. Roquefort Therapeutics holds an exclusive licence to the largest global IP portfolio on Midkine. The Midkine blocking drug development markets have significant global market potential (in the multi-billion dollars). Roquefort Therapeutics's pre-clinical programme is currently underway with an initial focus on cancer.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPDZGMNRLFGZZM